GlassScriptPhysician profile
Andre A Bonnecaze
NPI 1144221060
$3,514.96
in general payments reported to CMS, 2019-2025
55 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.52 · 2020: $55.70 · 2021: $15.13 · 2022: $163 · 2023: $837 · 2024: $1,123 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,182.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $376.81 | 2019-2025 | Imfinzi, Calquence, Enhertu |
| Genzyme Corporation | $217.73 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $204.76 | 2023-2025 | Keytruda, Reblozyl, Keytruda Qlex |
| Daiichi Sankyo INC. | $178.97 | 2023-2025 | Enhertu, Datroway |
| Genentech USA, INC. | $151.25 | 2024-2025 | Itovebi, Tecentriq, Phesgo |
| Janssen Biotech, INC. | $128.29 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Collegium Pharmaceutical, INC. | $122.08 | 2024-2025 | Belbuca |
| Novartis Pharmaceuticals Corporation | $119.01 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $107.70 | 2022-2025 | Fotivda |
| Glaxosmithkline, LLC. | $101.88 | 2019-2025 | Jemperli, Zejula |
| Beigene USA, INC. | $101.07 | 2023-2024 | Brukinsa |
| Incyte Corporation | $97.55 | 2023-2025 | Jakafi, Monjuvi |
| Abbvie INC. | $91.69 | 2024-2025 | |
| Cumberland Pharmaceuticals, INC. | $87.01 | 2024-2025 | Sancuso |
| Eisai INC. | $86.05 | 2023-2025 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Bonnecaze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.